Telavant: Roche To Buy Telavant From Roivant For Over $7 Billion

Roivant recently announced the entry into a definitive agreement with Roche to acquire Telavant Holdings (owned by Roivant Sciences Ltd. and Pfizer). The deal includes the development, manufacturing and commercialization rights in the US and Japan for RVT-3101, a novel TL1A directed antibody. And RVT-3101 is a promising new therapy in development for people suffering from inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The post Roche To Buy Telavant From Roivant For Over $7 Billion appeared first on Pulse 2.0.